semaglutide heart issues and the Heart: Focus on Their Love–Hate Relationship Semaglutide Demonstrates Impressive Heart Benefits

It is the worlds first triple hormone receptor agonist to reach Phase 3 clinical trials for obesity treatment

Weight-based dosing challenges, accelerated drug clearance, and adipose-driven immune activation all conspire to undermine therapeutic response

Antioxidants protect our bodies from oxidative stress

MNT had the opportunity to speak with Michael Snyder, MD, FACS, FASMBS, medical director of the Bariatric Surgery Center at Rose Medical Center, founder and director of the Denver Center for Bariatric Surgery Foundation, and in-house obesity specialist for FuturHealth, about this study

The FDA labeling for all semaglutide products cautions that delayed gastric emptying may impact the absorption of concomitantly administered oral medications